Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
Analysis of revenue contributions from different manufacturers in the market.
Self-administered Biologics Market Definition
The self-administered biologics market incorporates those biologics developed to be administered by the patient themselves, most commonly using prefilled syringes, auto-injectors, pens, and even portable injectors. The self-administration biology market is gaining traction, especially in the treatment of chronic diseases, owing to the increasing acceptance of subcutaneously administered biologics. This delivery mode has enhanced bioavailability and absorption rates, which is more suitable for the patients. Supportive studies on patients’ preference underscore this notion as it cuts down treatment costs and exudes the treatment flexibility in patients. This situation was aggravated by the COVID-19 pandemic where home healthcare solutions began to be embraced.
In August 2024, Novartis Pharma AG and Biotech Lindy Bios partnered to develop subcutaneous biologic injectables using Lindy Biosciences' proprietary microkarstification suspension technology, as part of a worldwide licensing agreement.
However, the thick nature of some biologics and the constraints imposed by the devices can pose a challenge on the growth of the self-administered biologics market. There is still a need for manufacturers to develop more advanced systems if they are to cater for biologics with varying characteristics and ensure self-administration by the patient is possible. New trims of self-administration devices in the form of electromechanical auto-injectors and large format ready to use cartridges enhance users’ convenience and compliance.
Download
Actionable Solutions
